在儿科急性胃肠炎中 Pleuran 的随机试验
Katarzyna Wzorek-Łyczko1, Anna Piwowarczyk2, Weronika Woźniak2
1The Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, 63A Żwirki & Wigury Street, Warsaw, 02-091, Poland. katarzynawzorek@vp.pl.
Scientific reports
|May 15, 2025
概括
普勒是一种潜在的免疫调节剂,并没有有效地减少儿童急性胃肠炎的持续时间或严重程度. 需要进一步的研究来探索其在儿科患者中作为营养药的使用.
科学领域:
- 免疫学 免疫学 免疫学
- 儿科 儿科 儿科
- 胃肠病学 胃肠病学
背景情况:
- 普勒因其免疫调节特性和安全性概况而闻名.
- 它在治疗急性胃肠炎的潜在应用,特别是在儿童中,需要进行调查.
研究的目的:
- 评估Pleuran在减少儿童急性传染性腹的持续时间和严重性的疗效.
- 评估Pleuran对住院率和需要静脉补水的需求的影响.
主要方法:
- 一个多中心,随机,双盲,安慰剂控制的优越性试验.
- 包括2-10岁的患有急性胃肠炎的儿童.
- 主要结局:腹的持续时间. 二次结果:严重程度,住院,需要补水.
主要成果:
- 27名儿童参加了这项研究.
- 在Pleuran和安慰剂组之间没有观察到腹持续时间,住院时间,静脉注射补水或症状严重程度的统计学上显著差异.
- 所有参与者都能很好地容忍Pleuran的使用.
结论:
- 在研究的儿科患者群体中,Pleuran作为急性胃肠炎的治疗方法显示出无效.
- 建议进行进一步的研究,以探索Pleuran作为儿科营养药的潜力.
相关概念视频
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975
Pharmacokinetics in Pediatric Patients: Drug Distribution
558
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
558
Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
Pharmacokinetics in Pediatric Patients: Drug Excretion
413
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
413
Acute Pyelonephritis II: Diagnostic Studies and Management
859
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
859
Bacterial Gastroenteritis
92
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid...
92


